EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

PET imaging of gliomas: Status quo and quo vadis?

Norbert Galldiks iD, Philipp Lohmann iD, Michel Friedrich, Jan-Michael Werner, Isabelle Stetter, Michael M Wollring, Garry Ceccon, Carina Stegmayr, Sandra Krause, Gereon R Fink, Ian Law, Karl-Josef Langen und 1 weitere

Neuro-Oncology · 09.12.2024 · 26 (Supplement_9) · S185-S198

DOI: 10.1093/neuonc/noae078 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 06.07.2024. Verfasst von Norbert Galldiks und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital of Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Positron-Emission Tomography. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PET imaging, particularly using amino acid tracers, has become a valuable adjunct to anatomical MRI in the clinical management of patients with glioma. Collaborative international efforts have led to the development of clinical and technical guidelines for PET imaging in gliomas. The increasing readiness of statutory health insurance agencies, especially in European countries, to reimburse amino acid PET underscores its growing importance in clinical practice. Integrating artificial intelligence and radiomics in PET imaging of patients with glioma may significantly improve tumor detection, segmentation, and response assessment. Efforts are ongoing to facilitate the clinical translation of these techniques. Considerable progress in computer technology developments (eg quantum computers) may be helpful to accelerate these efforts. Next-generation PET scanners, such as long-axial field-of-view PET/CT scanners, have improved image quality and body coverage and therefore expanded the spectrum of indications for PET imaging in Neuro-Oncology (eg PET imaging of the whole spine). Encouraging results of clinical trials in patients with glioma have prompted the development of PET tracers directing therapeutically relevant targets (eg the mutant isocitrate dehydrogenase) for novel anticancer agents in gliomas to improve response assessment. In addition, the success of theranostics for the treatment of extracranial neoplasms such as neuroendocrine tumors and prostate cancer has currently prompted efforts to translate this approach to patients with glioma. These advancements highlight the evolving role of PET imaging in Neuro-Oncology, offering insights into tumor biology and treatment response, thereby informing personalized patient care. Nevertheless, these innovations warrant further validation in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsPositron-Emission TomographyHumansRadiopharmaceuticals

Stichwörter der Autor:innen

IDHFETglioblastomasupercomputingvorasidenib

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Neurology, University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany.
  • Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
  • Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.
  • Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  • Department of Neurosurgery, University Hospital of Munich (LMU), Munich, Germany.

ORCID-Profile: Norbert Galldiks, Philipp Lohmann

Zitieren

APA

Galldiks, N., Lohmann, P., Friedrich, M., Werner, J. M., Stetter, I., Wollring, M. M., Ceccon, G., Stegmayr, C., Krause, S., Fink, G. R., Law, I., Langen, K. J., & Tonn, J. C. (2024). PET imaging of gliomas: Status quo and quo vadis?. Neuro-Oncology, 26(Supplement_9), S185-S198. https://doi.org/10.1093/neuonc/noae078

Vancouver

Galldiks N, Lohmann P, Friedrich M, Werner JM, Stetter I, Wollring MM, et al. PET imaging of gliomas: Status quo and quo vadis?. Neuro-Oncology. 2024;26(Supplement_9):S185-S198. doi:10.1093/neuonc/noae078

BibTeX
@article{Galldiks2024,
  author = {Galldiks, Norbert and Lohmann, Philipp and Friedrich, Michel and Werner, Jan-Michael and Stetter, Isabelle and Wollring, Michael M and Ceccon, Garry and Stegmayr, Carina and Krause, Sandra and Fink, Gereon R and Law, Ian and Langen, Karl-Josef and Tonn, Joerg-Christian},
  title = {PET imaging of gliomas: Status quo and quo vadis?},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {Supplement_9},
  pages = {S185--S198},
  doi = {10.1093/neuonc/noae078}
}
Kostenlos starten →